KemPharm, Inc.

Company Snapshot: KemPharm, Inc.

Last Change Volume High Low

Company Overview

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.

Client News

  1. May 15 2022 KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
  2. May 12 2022 KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
  3. May 11 2022 KemPharm to Present at Multiple Upcoming Investor Conferences
  4. May 5 2022 KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)